iRadimed Corporation (IRMD) and Tactile Systems Technology (TCMD) Head to Head Review
iRadimed Corporation (NASDAQ: IRMD) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitabiliy.
This is a summary of current ratings for iRadimed Corporation and Tactile Systems Technology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tactile Systems Technology||0||0||4||0||3.00|
iRadimed Corporation currently has a consensus price target of $12.00, indicating a potential upside of 19.40%. Tactile Systems Technology has a consensus price target of $33.00, indicating a potential downside of 0.99%. Given iRadimed Corporation’s higher probable upside, equities research analysts clearly believe iRadimed Corporation is more favorable than Tactile Systems Technology.
This table compares iRadimed Corporation and Tactile Systems Technology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tactile Systems Technology||2.24%||4.82%||3.28%|
Earnings and Valuation
This table compares iRadimed Corporation and Tactile Systems Technology’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|iRadimed Corporation||$24.35 million||4.41||$4.51 million||$0.24||41.88|
|Tactile Systems Technology||$90.69 million||6.23||$4.01 million||$0.09||370.37|
iRadimed Corporation has higher revenue, but lower earnings than Tactile Systems Technology. iRadimed Corporation is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
15.9% of iRadimed Corporation shares are owned by institutional investors. Comparatively, 34.7% of Tactile Systems Technology shares are owned by institutional investors. 60.1% of iRadimed Corporation shares are owned by insiders. Comparatively, 49.9% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
iRadimed Corporation beats Tactile Systems Technology on 7 of the 12 factors compared between the two stocks.
About iRadimed Corporation
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
About Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.